-
cutting edge design and process development capabilities to accelerate and bring the best in class medicines to patients around the world. ROLE SUMMARY As a member of our NGS and Data Science team, you will
-
cutting edge design and process development capabilities to accelerate and bring the best-in-class medicines to patients around the world. What You Will Achieve Pfizer's BioMedicine Design (BMD) is seeking
-
cutting edge design and process development capabilities to accelerate and bring the best in class medicines to patients around the world. ROLE SUMMARY As a member of our NGS and Data Science team, you will
-
to support decision making in the drug development process. The General Toxicology R6 Study Director is responsible for the design, conduct, interpretation, and reporting of exploratory, mechanistic and GLP in
-
cutting edge design and process development capabilities to accelerate and bring the best in class medicines to patients around the world. What You Will Achieve Drug Safety Research & Development (DSRD) is
-
contemporary design tools to drive effective target design and prioritization within a portfolio of projects Contribute to ADC payload strategy and utilize experience in synthetic chemistry and methodology
-
-leading team whose mission is to identify key risks associated with unwanted clinical immunogenicity and influence drug design to mitigate those risks. We are currently seeking an experienced immunogenicity
-
cutting edge design and process development capabilities to accelerate and bring the best in class medicines to patients around the world. What You Will Achieve You will participate in pre-clinical oncology
-
cutting edge design and process development capabilities to accelerate and bring the best in class medicines to patients around the world. What You Will Achieve The ADC Chemistry (AC) group is seeking a
-
partners to design imaging and experimental therapeutics studies, and will be responsible for the execution, analysis, and generation of reports for studies. Dana-Farber Cancer Institute supports a robust